Innovent Biologics, IASO Bio strengthen collaboration with equity investment and licensing deal
Innovent Biologics, Inc. (HKEX: 01801), a globally recognized biopharmaceutical company, and IASO Biotechnology, a leader in innovative cell therapies and antibody products, have announced a significant enhancement in their partnership. This collaboration includes IASO Bio’s acquisition of certain rights to FUCASO (Equecabtagene Autoleucel) from Innovent, along with a license for the associated intellectual property, coupled […]